The University of Queensland

Amrad Corporation Limited

The Council of the Queensland Institute of Medical Research

The University of Melbourne

Walter and Eliza Hall Institute of Medical Research

Zenyth Operations Pty. Ltd.

Perry Francis Bartlett

Andrew W Boyd

Mark Murphy

Manuel Baca

Trevor Kilpatrick

Mirella Dottori

Lynne Hartley

George Paxinos

Mary P Galea

Ursula Greferath

Jason Coonan

Frank Kontgen

Mark Pouzzotto

Cheema Surindar

Katrina Fieldew

Elizabeth Jane Coulson

Andrew Donald Nash

Douglas James Hilton

Louis Jerry Fabri

Ora Bernard

Masakazu Hasegawa

Melissa Brown

Yasuhiko Nakata

Kate Reid

Kim Maree Jachno

Rodney Lee Rietze

Dhanisha Jhaveri

Tara Louise Walker

Leanne Cooper

Mike Gerometta

The present disclosure relates generally to the treatment of diseases and conditions exacerbated by signalling via the erythropoietin-producing-hepatoma receptor kinases EphA4 and to agents useful in such treatment.

Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof

The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.

Latent neural stem cell population

A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a &#x3b2;3 adrenergic receptor agonist.

Neuronal stimulation

The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75. These molecules antagonise p75-mediated cell death.

Method of modulating cell survival and reagents useful for same

The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75. These molecules antagonise p75-mediated cell death.

The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.

Method of treatment

The present invention relates generally to a method for the generation of a substantially homogeneous population of undifferentiated cells. More particularly, the present invention relates to the purification of a substantially homogeneous population of stem cells and their progenitor or precursor cells. Even more particularly, the present invention provides a population of neural stem cells (NSCs). The subject invention is particularly directed to NSCs and precursor cells with the capacity to differentiate into cells and cell lineages required for the development, maintenance or repair of the central nervous system in an animal such as a mammal. The present invention is further directed to NSCs and progenitor and/or precursor cells which are capable of proliferation and differentiation into multiple cell lineages, such as but not limited to neurons, oligodendrocytes, glia and astrocytes. The subject invention further contemplates the use of NSCs and/or precursor cells for the repair or regeneration of tissue, such as tissue associated with the central nervous system, in an animal including a mammal. The NSCs of the present invention may be used to identify naturally occurring molecules such as cytokines as well as molecules obtained from natural product screening or screening of chemical libraries which induce proliferation of the NSCs. Such molecules are useful in the development of therapeutics.

Method of purification of cells

The present invention relates generally to a biologically active complex comprising at least two heterologous molecules. More particularly, the biologically active complex of the present invention comprises at least two polypeptides or parts, fragments, truncates or protease-activated forms of one or more of the polypeptides wherein the complex alone or in association with a receptor, ligand or other molecule facilitates proliferation, differentiation and/or survival of a cell. The identification of the biologically active complex of the present invention permits the assay for agonists and antagonists of the formation of the biologically active complex as well as therapeutic and diagnostic reagents based on the biologically active complex or interaction between the biologically active complex and a receptor, ligand or other molecule.

Biologically active complex of NR6 and cardiotrophin-like-cytokine

The present invention relates to a method for regulating neuron development/maintenance and/or regeneration in a nervous system of a mammal and to pharmaceutical compositions comprising leukaemia inhibitory factor useful for same.

Method for regulating neuron development and maintenance

The present invention provides methods for regulating neuron development, regeneration and maintenance by administration of leukemia inhibitory factor (LIF). Pharmaceutical compositions containing LIF and one or more additional neuron stimulating factors are also provided.

The present invention relates to a method for regulating neuron development, maintenance and regeneration in the central and peripheral nervous systems of a mammal and to pharmaceutical compositions comprising leukaemia inhibitory factor with or without nerve growth factor useful for same. The present invention is particularly useful in the treatment of developmental and cerebral anomalies and neuropathies in mammals and in particular humans.

Methods for promoting functional regeneration of mammalian muscle by

A method for the in vitro production of lines of immortalized neural precursor cells, including cell lines having neuronal and/or glial cell characteristics, comprises the step of infecting neuroepithelium or neural crest cells with a retroviral vector carrying a member of the myc family of oncogenes.

Growing community of inventors

North Carlton, Australia

Perry Francis Bartlett